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Abstract
While standard meta-analysis pools the results from randomized trials
that compare two treatments, network meta-analysis aggregates the results
of randomized trials comparing a wider variety of treatment options. How-
ever, it is unclear whether the aggregation of effect estimates across hetero-
geneous populations will be consistent for a meaningful parameter when not
all treatments are evaluated on each population. Drawing from counterfac-
tual theory and the causal inference framework, we define the population of
interest in a network meta-analysis and define the target parameter under a
series of nonparametric structural assumptions. This allows us to determine
the requirements for identifiability of this parameter, enabling a descrip-
tion of the conditions under which network meta-analysis is appropriate and
when it might mislead decision making. We then adapt several modeling
strategies from the causal inference literature to obtain consistent estimation
of the intervention-specific mean outcome and model-independent contrasts
between treatments. Finally, we perform a reanalysis of a systematic review
to compare the efficacy of antibiotics on suspected or confirmed methicillin-
resistant Staphylococcus aureus in hospitalized patients.
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1 Introduction
While individual studies are rarely used to inform scientific or medical decision
making (Slavin, 1995), multiple sources of evidence may be aggregated in order
to offer more generalizable and precise comparisons between treatments (Lum-
ley, 2004, Salanti et al., 2008, Caldwell et al., 2005, Lu and Ades, 2004). Meta-
analysis, which is the statistical synthesis of multiple study results, is often con-
sidered the highest form of quantitative evidence due to its ability to combine all
relevant information in the scientific literature. However, because of such issues
as effect heterogeneity across study populations and methodology that does not
necessarily account for all sources of bias, the status of meta-analysis as the “gold
standard” of medical knowledge has been questioned (Berlin and Golub, 2014).
Standard meta-analysis compares two treatments of interest (or, for instance,
an active treatment and placebo). When many treatments for a common condition
are tested and made available over time, the medical literature may then contain
multiple randomized controlled trials (RCTs) with various treatment comparisons
on potentially different populations. Without additional guidance, clinicians and
patients are left to informally synthesize information in the available studies in
order to determine an optimal treatment decision. A network meta-analysis statis-
tically aggregates the results from the relevant RCTs in order to obtain an estimate
of the contrast between each pair of treatments. In particular, this type of analysis
can produce estimates of contrasts even when no RCT directly compared the two
treatments of interest directly.
Each RCT in the network may be performed on populations that differ in terms
of their baseline characteristics. These population-specific variables may affect
the average response to treatment so that in order to combine inference involv-
ing the means, it might be beneficial to control for such variables (Salanti et al.,
2009). Furthermore, it has been noted that if these characteristics not only dif-
ferentially affect response to treatment, but also the initial study design choice
of which treatments to compare, then these variables may confound the overall
effect estimate (Jansen et al., 2012, Berlin and Golub, 2014). As an example,
Jansen et al. (2012) suggest that the baseline severity of patients recruited into a
study can be related to the type of treatments investigated in the study and also af-
fect the average outcome at the end of the study. As we demonstrate in this paper,
such “study-level confounding” must be adjusted for in order to obtain consistent
estimation of average treatment effects.
In this paper, we consider the setting where individual patient data are not
available so that the observed data is limited to average covariate and outcome
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values in addition to study-level information (which we refer to as “aggregate” or
study-level data). We begin by describing past parametric approaches to network
meta-analysis where the parameter of interest is dependent on the model speci-
fication and where the absence of effect heterogeneity is often required a priori.
Using the counterfactual framework, we propose a novel definition of a marginal
and model-independent causal parameter of interest in network meta-analysis and
delineate the assumptions required to estimate this parameter in the presence of
measured study-level confounders. We are then able to clarify conditions under
which a network meta-analysis is appropriate and when it might mislead decision
making regardless of estimation method used. We describe several marginal esti-
mation methods adapted from the single study causal inference setting, including
a doubly robust and semiparametric locally efficient Targeted Maximum Likeli-
hood Estimator, and then compare these methods in a simulation study. Finally,
we perform a reanalysis of the systematic review by Bally et al. (2012) to compare
the efficacy of antibiotics on suspected or confirmed methicillin-resistant Staphy-
lococcus aureus (MRSA) in hospitalized patients.
2 The observed data
Each RCT is assumed to randomly sample subjects from a wider population,
called a superpopulation. Within the RCT, randomization assigns subjects to two
or more groups, each one receiving a treatment. These groups are often referred
to as treatment arms. Due to randomization and random sampling, each group
is a representative sample from the superpopulation. Therefore, each arm can be
thought of as a distinct study on the same superpopulation. The superpopula-
tions targeted by the RCTs may differ in terms of their characteristics due to, for
example, each trial’s physical and temporal location, the individual inclusion and
exclusion criteria, and the recruitment sample size targets. Therefore, if effect het-
erogeneity exists (i.e. if the relative treatment effects at the subject level depend
on baseline covariate values), one would not expect the average relative treatment
effects to necessarily be equal across superpopulations.
More formally, the superpopulation is the conceptual group of essentially in-
finite size from which the study sample is selected (Robins, 1988). A measure of
some outcome (Y ) is taken on each subject in the RCT arm. In this article, we will
generally consider the example where the sample mean and standard deviation of
Y are the summary statistics computed in each RCT.
Let Ai j be the intervention received by subjects in arm j of a particular RCT in-
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dexed by i. For this arm, we observe an estimated mean outcome Y¯i j and standard
deviation Si j. Let Oi = (Wi,ni,{Ni j,Ai j,Y¯i j,Si j}; j = 1, ...,ni), i = 1, ...,N where
Wi is study baseline information and ni is the number of arms in the study. For the
j−th arm of RCT i, let Ni j be the number of subjects and N be the total number
of RCTs in the sample.
Because we are interested in summarizing effects across multiple superpop-
ulations, we are arguably attempting to estimate effects in a metapopulation that
contains the individual superpopulations from each study. For the purpose of this
paper, we define the metapopulation as the union of possible study superpopula-
tions and define our parameters of interest with respect to this metapopulation. In
particular, we assume that the individual Oi vectors are independently drawn from
the metapopulation and identically distributed.
3 Past approaches to network meta-analysis
Standard approaches in network meta-analysis where only aggregate data are
observed place a hierarchical model on either the study-specific contrasts (e.g. the
difference in means, Y¯i1− Y¯i2) or the arm-specific outcomes (Y¯i j) and specify a
within-study correlation structure (Lu and Ades, 2004, Salanti et al., 2008, Dias
et al., 2013a, Zhang et al., 2014). As the absence of effect heterogeneity is often
required, a priori (Cope et al., 2014) and post-hoc (Lu and Ades, 2006) inves-
tigation of this assumption is routinely recommended. The reader is referred to
published guidance (Dias et al., 2013b, Jansen et al., 2014) and to an example
of how heterogeneity was accounted for in an economic analysis (Welton et al.,
2015). There has been recent heated debate about the appropriateness of arm-
based estimation methods (Dias et al., 2013a, Hong et al., 2016).
The effect targeted in a hierarchical model depends on the contrast-type cho-
sen and the parametrization of the model, and may or may not correspond to a
marginal effect as we define further on. For binary outcomes, due to the non-
collapsibility of the logistic regression model (Gail et al., 1984) in particular, ad-
justment for covariates in such a model changes the true value of the “effect”
parameter being estimated. This type of modeling strategy may therefore be bi-
ased for the estimation of a marginal effect. Even in linear models, the inclusion
of treatment interactions with covariates can also bias the value of the coefficient
of treatment relative to the marginal effect. Zhang et al. (2014) and Zhang et al.
(2015) take a missing data perspective and model the arm-specific outcomes us-
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ing a Bayesian hierarchical model to estimate marginal parameters. While neither
approach has yet been extended to incorporate covariates, the former paper as-
sumes that treatments are applied to studies at-random while the latter allows for
estimation in a not-at-random context by explicitly specifying the unobservable
selection mechanism.
While adjustment for covariates is rare in practice, Jansen et al. (2012) in-
troduced the notion of adapting Pearl’s causal directed acyclic graphs (DAGs) to
this setting (Pearl, 2009) in order to assist in covariate selection. As a general
rule, Jansen et al. (2012) advocate for the adjustment of all modifiers of the rel-
ative treatment effects across comparisons. They also discourage adjustment for
covariates that are not effect modifiers due to the fact that they may induce bias in
the meta-analysis.
4 The counterfactual approach
Let Y a be the potential (or counterfactual) outcome of a random subject drawn
from the metapopulation had that subject received treatment A = a. In an RCT,
each study arm produces an estimate of the superpopulation-specific mean of the
outcome Y a under the treatment assigned. Let the true mean of the potential out-
come under treatment a for the superpopulation targeted in study i be denoted
Mai := E(Y
a | Pi) where Pi represents the superpopulation targeted in study i.
Let Σai :=
√
Var(Y a | Pi) be the standard deviation of the potential outcomes in
Pi under treatment a. Now suppose that each superpopulation is independently
drawn from a metapopulation, P =
⋃
i∈sP Pi, the union of all possible study su-
perpopulations indexed by the set sP. A marginal target parameter in a meta-
analysis is Ma := E(Y a) = E(Mai ), which represents the mean outcome under
treatment a on the metapopulation. The standard deviation of the overall out-
come distribution is Σa :=
√
Var(Y a) =
√
E{Var(Y a | Pi)}+Var{E(Y a | Pi)} =√
E(Σai
2)+Var(Mai ), representing the within and between study heterogeneity in
the outcome under treatment. Due to treatment arm randomization and random
sampling, Y¯i j is an unbiased estimate of M
Ai j
i , the mean potential outcome un-
der the observed treatment, and Si j is a consistent estimate of Σ
Ai j
i , the potential
standard deviation under the observed treatment.
For two treatments, A = a and b, with corresponding means Ma and Mb, we
can define a causal effect as the contrast between the mean outcome when the
entire metapopulation is treated according to one treatment versus another. For
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instance, for binary outcomes we may define the causal risk difference as Ma−Mb
and the causal risk ratio as Ma/Mb.
The patient sample in any given study arm may not be representative of the
metapopulation, for which the effect of interest is defined. In addition, because
treatment was not randomly allocated across different RCTs, the collection of
mean outcomes observed under a given treatment a may not be representative
of the metapopulation under treatment a. At the design stage, the decision of
which treatments to include as arms within an RCT may be influenced by the
characteristics of the superpopulation on which the study is taking place. For
instance, consider the example of planning a study for a superpopulation with
higher disease severity from Jansen et al. (2012). Studies including patients with
severe disease are more likely to include an arm with an aggressive treatment. If
this occurs, the mean outcome under the aggressive treatment may be different
than in a less severe superpopulation. In this situation, we would say that the
treatment-mean outcome relationship is confounded at the study level by severity.
4.1 A Causal Directed Acyclic Graph (DAG) for network meta-
analysis
Similar to Alonso et al. (2015), we assume that heterogeneity in the different su-
perpopulations targeted in the individual RCTs implies that each RCT estimates
a different causal effect. Like Zhang et al. (2014), we take an “arm-based” ap-
proach to the problem. Like Jansen et al. (2012), we draw a causal DAG in order
to conceptualize the relationship between treatment, study results, and population-
specific characteristics. We arbitrarily choose to intervene on the arm labeled j in
each study. We write Ni = {Ni j, j = 1, ...,ni}, the vector of sample sizes across
arms. We will also define Ai = {Ai j, j = 1, ...,ni}, the vector of treatment assign-
ments evaluated in study i, and Ai\ j to mean the treatment vector excluding some
arm j.
Many of the assumptions presented in detail in Section 4.3 are drawn explic-
itly using the study-level DAGs in Figure 1(a). The nodes of the DAG represent
variables measured at the level of the RCT and the arrows between them represent
the effect of the parent on the child node. For example, the absence of an arrow
from Ai\ j to Y¯i j,Si j represents a component of the “no interference” assumption
that the treatment in one arm will not affect the outcome in another. The arrow
from Ni j to Y¯i j,Si j is present because the sample size within a study arm will affect
the distribution of the outcome summary statistics.
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(a) (b)
Figure 1: a) The study-level DAG reflecting the unconfoundedness and time-
ordering assumptions made in Sections 4.3 and 4.2 without assuming indepen-
dence between the sample mean and standard deviation within a study arm. b) The
simplified DAG that arises from assuming the independence between the sample
mean and standard deviation. Here, W1i, W2i and W3i are baseline covariates, Ai j
and Ai\ j are the treatments assigned to arms j and the non- j arm(s), respectively,
Ni j is the sample size of arm j, Y¯i j is the mean outcome and Si j is the estimated
standard error of the outcome of arm j.
The sample size node Ni j is determined by the sample size calculation made in
the study design phase and also by the success of recruitment. This calculation is
inherently conditional on the superpopulation being evaluated, as superpopulation
characteristics are taken into account when hypothesizing an effect size and stan-
dard error. This calculation is also conditional on the treatments being compared.
Causal DAGs can be used as a tool to identify which variables must be con-
trolled for in the meta-analysis in order to estimate the treatment-specific metapop-
ulation mean outcome. Depending on some underlying statistical assumptions
that we will investigate in detail in the following sections, these DAGs may sim-
plify to Figure 1(b). This happens because we can ignore the mediation path
through Ni j in order to estimate the total effect of the treatment on outcome. Under
these conditions, assuming independence between the variables in Wi, the analy-
sis must adjust for all common causes of treatment selection and study outcome
distribution.
Note that the recommendations based on this DAG differ from those of Jansen
et al. (2012), who say that the analysis must adjust exclusively for effect modifiers.
The assumptions that we list in Section 4.3 are explicitly required in the steps we
take in Section 4.2 in order to obtain identifiability of the meta-analysis parameter
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of interest.
4.2 The G-formula and nonparametric identifiability
Suppose we observe the aggregate data Oi, i = 1, ...,N, independently drawn
and identically distributed. Using the nonparametric structural equation modeling
(NPSEM) of Pearl (2009), the metapopulation mean outcome, Ma, can be shown
to be identifiable (that is, known with infinite data) under the several conditions
outlined and discussed in Section 4.3.
4.2.1 The observed data generation
At the study design stage for RCT i, the superpopulation Pi is randomly drawn
from the metapopulation P . The selection of Pi determines the population-level
covariates Wi. The number of study arms ni and the treatments compared in the
study, the multivariate Ai = {Ai j, j = 1, ...,ni}, are drawn conditional on Wi. The
sample size calculation is carried out based on the choice of treatment compari-
son and on the sub-population characteristics (i.e. based on the expected effect and
precision in that sub-population). This calculation is approximate and the result-
ing sample size also depends on the success of recruitment. Therefore, the sample
sizes for the treatment arms, Ni, are not deterministic, but are drawn conditional
on Ai, ni and Wi.
The second stage operates at the individual level once subjects are recruited
and randomly assigned treatment. Suppose each subject k in arm j of study i has
continuous outcome Yi jk,k = 1, ...,Ni j (under treatment Ai j). Each Yi jk is indepen-
dently drawn from a distribution with mean MAi ji and standard deviation Σ
Ai j
i . The
empirical mean outcome in arm j of study i is therefore Y¯i j = 1/Ni j∑k Yi jk. The
standard deviation is estimated as S2i j = 1/(Ni j−1)∑k(Yi jk− Y¯i j)2. In addition,
subject recruitment yields summary characteristics of the superpopulation, which
we assume to include complete information about the covariates Wi that were
known at study conception and contributed to the treatment choice. We assume in
the following that we do not observe the subject-level data.
Let ωi j represent the set of estimated summary statistics of the outcome vari-
able from study i arm j. For instance, we might have that ωi j = {Y¯i j,Si j}. Corre-
spondingly, let ωai j be the set of estimates of the counterfactual summary statistics
that would arise had arm j been assigned treatment a.
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Assuming no interference between arms and that the distribution of ωi j in one
arm of a study is conditionally independent of the outcomes in the others and also
independent of the total number of arms, the NPSEM that we assume can then be
written as
Wi = fW (εW )
ni = fn(Wi,εn)
Ai = fA(ni,Wi,εA)
Ni = fN(Ai,ni,Wi,εN), for j = 1, ...,ni
ωi j = fω(Ni j,Ai j,Wi,εω), for j = 1, ...,ni
The probability density function f (Oi) arising from the NPSEM without in-
tervention can be decomposed as
f (Oi) =QW (Wi)Qn(ni |Wi)gA(Ai | ni,Wi)×
QN(Ni | Ai,ni,Wi)
ni
∏
j=1
Qω(ωi j | Ni j,Ai j,Wi)
where QW (Wi) corresponds to the density function for Wi, Qn(ni |Wi) corresponds
to the density function for ni conditional on Wi, and gA(Ai | ni,Wi) corresponds to
the conditional density function for Ai. Within each RCT, QN(Ni | Ai j,Ai\ j,ni,Wi)
corresponds to the conditional density function for Ni and Qω(ωi j | Ni j,Ai j,Wi) is
the conditional (joint) density for the measured summary statistic(s) in arm j.
4.2.2 The counterfactual distribution
Define an intervention as the assignment of treatment strategy a to an arbitrary
arm in each study. In other words, for all i we set Ai j = a for a single arbitrary
arm j. The remaining non- j arms receive potential treatments Aai\ j. The joint
density for the counterfactual data Oai =(Wi,ni,A
a
i\ j,{ωai j∗ ,Nai j∗; j∗= 1, ...,ni}) can
be obtained through the G-formula (Robins, 1986). This joint density function can
be written as
f (Oai ) =QW (Wi)Qn(ni |Wi)gA\ j(Aai\ j | ni,Wi)QN(Nai | Aai\ j,ni,Wi)Qω(ωai j | Nai j,Wi)×
∏
j∗ 6= j
Qω(ωai j∗ | Nai j∗ ,Aai j∗,Wi)QN(Nai j∗ | Aai\ j,ni,Wi)
where gA\ j(Aai\ j | ni,Wi) is defined as the conditional (joint) density of the treat-
ments assigned to non- j arms.
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4.2.3 Identifiability for conditionally independent Y¯ and S
Suppose we have that ωi j = {Y¯i j,Si j}, meaning that each study reported the sam-
ple means and sample standard deviations of a continuous outcome. We then make
the key structural assumption that Y¯ ai j⊥⊥Sai j |Nai j,Wi where Nai j is the counterfactual
sample size in study i arm j. Let Y ai jk represent an individual recruited into study
i arm j in the counterfactual scenario. The independence assumption arises natu-
rally from the distributional assumption that Y ai jk ∼N (Mai ,(Σai )2) because Y¯ ai j and
Sai j are the sample mean and standard deviation in superpopulation Pi when a is
the treatment assigned. Asymptotically, we have that Y¯ ai j and S
a
i j are independent
normal variables when the subject-level outcomes are drawn from a distribution
with zero skew, such that E{(Y ai jk)3} = 0 (Ferguson, 1996, p. 46). We show in
Appendix A.1 that under this assumption f (Oai ) can be decomposed in such a way
that the mean outcome, E(Y¯ ai j) = M
a, can be written independently of the non- j
arms, resulting in the simple equality Ma =
∫
W E(Y¯
a
i j | Nai j,Wi)QW (Wi)dW . Under
the unconfoundedness assumption Y¯ ai j⊥⊥Ai j = a | Nai j,Wi, and under the consis-
tency assumption (see next section) we may write the G-formula (Robins, 1986)
Ma =
∫
Wi E(Y¯i j |Wi,Ai j = a)QW (Wi)dWi. Therefore, this quantity is identifiable
from the data.
Identifiability without assuming this structural independence is possible, and
we describe the additional causal assumptions required for this setting in Ap-
pendix A.2.
4.2.4 Identifiability for binary outcomes
If the original study outcomes are binary (such that Yi jk = {0,1}), the study means
Y¯i j are the proportions of subjects with the indicated outcome. Therefore, Nai jY¯
a
i j
has a binomial distribution with true probability of outcome Mai = E(Y
a | Pi).
Then, Σai =
√
Var(Y a | Pi) =
√
Mai (1−Mai ). Similarly, the study arm estimate
of the standard deviation is Sai j =
√
Y¯ ai j(1− Y¯ ai j). In this case, the likelihood will
not include a component for Si j so no independence assumption is necessary. The
resulting G-formula is still Ma =
∫
Wi E(Y¯i j | Ni j,Wi,Ai j = a)QW (Wi)dWi and will
rely on the same unconfoundedness assumption that Y¯ ai j⊥⊥Ai j = a | Ni j,Wi.
10
4.3 Assumptions
For convenience, here we list the assumptions needed for the identification of
Ma, corresponding with the NPSEM in Section 4.2.1 and the DAGs in Figure 1.
We also comment on the meaning and plausibility of these assumptions in the
hypothetical situation where each individual RCT has full compliance. Under full
compliance, each RCT arm produces a consistent estimate of the mean outcome
in the superpopulation under full adherence to the assigned treatment.
No interference. The use of the above counterfactual notation presupposes
that the treatment assigned to one study does not affect the counterfactual out-
come of another study (Rubin, 1980). A secondary level of interference within an
individual study involves the treatment in one study arm affecting the outcomes
in another study arm. This means that the estimates Y¯ ai j and S
a
i j do not depend on
the treatment received by another arm of the same RCT. The assumption of no
interference will generally not hold for certain studies of infectious disease. For
example, an effective vaccine in one arm may impact the outcome of an unvac-
cinated subject in the control arm, because the unvaccinated subject will be less
likely to be exposed to the disease through herd immunity.
Unconfoundedness. (Weak) unconfoundedness (Imbens, 2000) is required for
the identification of Ma. In this context, unconfoundedness is the assumption that
the counterfactual sample means under a treatment a are independent of the true
treatment received conditional on measured covariates. Specifically, this means
that Y¯ ai j⊥⊥Ai j = a | Nai j,Wi. In the example DAG of Figure 1(a), this corresponds
to measuring all the components of node W2i. The validity of this assumption is
entirely dependent on the subject-matter, how RCTs in the field are designed, and
on the information reported in the RCTs.
Consistency. The consistency assumption in this context states that the coun-
terfactual mean of a study arm under a given treatment is the same as the observed
result. With notation, this is equivalent to stating that Y¯ ai j = Y¯i j when Ai j = a.
Having different definitions of treatment across studies may violate this assump-
tion if all are categorized under the same treatment type and this variation has
an impact on the outcome (Cole and Frangakis, 2009). For example, there may
be different drug dosages and lengths of follow-up across studies. Disregarding
these differences will violate consistency if the various treatment-types have dif-
ferential effects on the patient outcomes. With some additional unconfoundedness
requirements, one might surmount this obstacle using the approach described in
VanderWeele and Herna´n (2013). (Note that this definition of consistency corre-
sponds with the causal assumption and is distinct from the network meta-analysis
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meaning of the term in e.g. Lu and Ades 2006.)
Positivity. Finally, we need to evaluate both theoretical and practical positiv-
ity. Theoretical positivity is the assumption that, conditional only on variables
required for unconfoundedness, all studies had a positive probability of being as-
signed each treatment under investigation. Practical positivity is the condition that
for every level of the characteristics Wi, there is an estimated positive probability
of receiving treatment.
It is important to note that treatment comparisons are based on the same P
and that the target parameter Ma = E(Mai ) relies on the definition of this metapop-
ulation. If positivity does not hold on some subpopulations it would be necessary
to exclude all studies (and corresponding superpopulations) that contain such sub-
populations.
It is furthermore important to note that the positivity assumption is not the
same as requiring that all studies could have realistically been assigned each treat-
ment. In particular, certain treatments may not have been available when some
older trials were carried out. If year of study is not required to unconfound the
analysis, then the unconditional probability may still be non-zero.
5 Estimation of the treatment-specific metapopula-
tion mean outcome
5.1 G-Computation
G-Computation procedures based on the G-formula in Section 4.2 can be used to
estimate the target parameter. Here we define a simple procedure resulting from
the data requirement that the sample mean and standard deviation are independent
within a study arm. This procedure allows for simple frequentist estimation of the
mean effect of treatment.
This procedure requires estimates for the conditional expectation E(Y¯i j |Wi,Ni j,Ai j =
a) for a given value of treatment. First we must note that while the conditional
mean of Y¯i j is independent of Ni j, its distribution is not. In particular, we have that
Var(Y¯i j |Wi,Ni j,Ai j) = 1Ni j Var(Yi jk |Wi,Ni j,Ai j) =
1
Ni j
(ΣAi ji )
2.
Because S2i j is a consistent estimate of the superpopulation-level variance under
treatment Ai j, we are able to estimate this variance.
12
A model for the regression on Y¯i j may be fit by pooling over all arms regardless
of treatment assignment. In order to obtain the Best Linear Unbiased Estimator,
we can weight by Ni j/S2i j. Using this model fit, we predict
ˆ¯Y ai = Eˆ(Y¯i j |Wi,Ai j =
a), i.e. the predicted mean under treatment a for each study. The G-Computation
estimate is then MˆaGCOMP = 1/N∑
N
i=1
ˆ¯Y ai .
The standard error for the G-Computation estimate is usually computed through
nonparametric bootstrap methods (Snowden et al., 2011). Bootstrap resampling
must be done by resampling studies, rather than arms, similar to what is done in a
study with clustering (Efron and Tibshirani, 1994).
5.2 Inverse probability of treatment weighting
Likelihood methods, such as G-Computation, require correct parametric specifi-
cation of the outcome model, which may be difficult to specify. An alternative
approach is to utilize propensity score methods, which require the estimation of
a model for the treatment received by the arm. For a given treatment type a, let
ga(Wi) be an estimate of the probability P(a ∈ Ai |Wi), called the generalized
propensity score (Imbens, 2000).
Despite the small sample size in standard network meta-analysis, one might
attempt inverse probability of treatment weighting (IPTW) for the estimation of
the marginal parameter. Let Y¯ ai represent the observed outcome of the arm of
study i that received treatment a (or N/A if no arm of study i received treatment
a). An IPTW estimator for multiple treatments (Imbens, 2000) can be represented
as
MˆaIPTW = 1/N
N
∑
i=1
I(a ∈ Ai)Y¯ ai
ga(Wi)
.
Intuitively, this estimator takes a mean of Y¯i j with only the arms treated according
to Ai j = a. It then adjusts this estimate to remove the confounding bias caused by
the baseline variables.
The consistency of this estimator can be shown as follows.
MˆaIPTW
P−→ E
[
Y¯ ai I(a ∈ Ai)
P(a ∈ Ai |Wi)
]
= E
{
Y¯ ai E
[
I(a ∈ Ai)
P(a ∈ Ai |Wi)
∣∣∣∣Y¯ ai ,Wi]}= E (Y¯ ai ) = Ma.
5.3 Targeted Minimum Loss-based Estimation
Targeted Minimum Loss-based Estimation (TMLE) (van der Laan and Rubin,
2006, van der Laan and Rose, 2011) is a framework for the construction of semi-
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parametric estimators generally applied to the estimation of causal quantities. The
TMLE procedure is carried out by first fitting a model for the expected value of
the arm-based means, E(Y¯i j |Wi,Ai j = a) which, under the causal assumptions,
can equivalently be written as the expectation of the potential outcome had the
study evaluated treatment a, E(Y¯ ai |Wi,a ∈ Ai). As in the G-Computation proce-
dure, this model can be estimated by weighing each observation by Ni j/S2i j. For
each arm in the study, we use this model to obtain ˆ¯Y ai , predictions of the sample
mean of each trial i under treatment a. These predictions are then updated by
fitting a no-intercept logistic regression using study arms that evaluated treatment
a. This logistic regression is fit with outcome Y¯i j, offset logit( ˆ¯Y ai ), and single
covariate g−1a (Wi), corresponding with the inverse probability weights. Denote
the estimate of the coefficient from this regression as εˆ . The updated predictions
are then logit( ˆ¯Y a,∗i ) = logit(
ˆ¯Y ai )+ εˆ/ga(Wi), which is calculated for each study.
The final targeted estimate for Ma is MˆaT MLE = 1/N∑
N
i=1
ˆ¯Y a,∗i . Note that in order
to perform the update step, the means and outcome must be transformed to (0,1)
and then subsequently transformed back to the original scale (Gruber and van der
Laan, 2010). This can be done using real or empirical bounds.
This TMLE is consistent under correct specification of the propensity score
model or the model for the expected value of the mean outcome (the property of
double robustness). If both of these models are correct, then TMLE is asymp-
totically efficient in the class of regular, asymptotically linear estimators in the
semiparametric model space (van der Laan and Rose, 2011). More details and a
proof of consistency are included in Appendix A.3.
6 Simulation study
In this section we demonstrate that we can obtain consistent estimation of the
target parameter Ma = E(Y a) under the NPSEM using the proposed estimators.
We also compare the efficiency of each approach.
While the proposed estimators do not restrict the number of study arms, we
fix all simulated studies to have exactly two treatment arms for simplicity. We are
interested in estimating the mean outcome of the metapopulation under treatment
for each of four treatments of interest. For each study i = 1, ...,N, we generate
the population average characteristic, Wi from a Poisson distribution with mean 2.
The probabilities of receiving a given treatment are calculated conditional on the
value of Wi. Two treatment options Ai are then sampled without replacement using
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Table 1: Simulation study: data generation
Variable Study design: for each i = 1, ...,N
Number of arms ni = 2
Study-level covariate Wi ∼ Poisson(µ = 2)
Treatments
Ai = (Ai1,Ai2) sampled without replacement with probabilities
p1 = logit−1(0.4Wi)
p2 = logit−1(−0.4Wi)
p3 = logit−1(0.8Wi)
p4 = logit−1(−0.8Wi)
Sample size
(study recruitement)
Ni ∼ Poisson(µ = 5000exp(−0.4W − sum(γ[Ai j])))
where γ = (−1.5,1,−1,1)
Within-study: for each j = 1,2, k = 1, ...,Ni
Subject-level covariate Xi jk ∼ N(µ =Wi,σ2 = 4)
Subject-level outcome
Yi jk ∼ N(µ = Xi jk +β [Ai j],σ2 = 1)
where β = (0.8,0.2,1,−0.5)
Observed data: for each i = 1, ...,N, j = 1,2
Study-level information
Wi, Ai, and Y¯i j where
Y¯i j = 1/Ni∑Nik=1Yi jk
the calculated probabilities. Treatments 2 and 4 are generated to be less likely to
be chosen with larger Wi. The sample size Ni (which we allowed to be common
to both arms in the study) is drawn from a Poisson distribution with mean linear
in Wi and Ai. For each subject within each arm, we draw a baseline covariate
Xi jk from a Gaussian distribution with mean Wi and constant variance. We set
β = (0.8,0.2,1,−0.05) to be the treatment-specific coefficients. Outcome values
Yi jk are drawn from a Gaussian: Yi jk ∼N (Xi jk + β [Ai j],1). A summary of the
data-generation is presented in Table 1.
The sample statistics from each study arm are calculated by taking the mean
and standard deviation of Yi jk within each arm. The true treatment-specific super-
population means are M1 = 2.80,M2 = 2.20,M3 = 3.00,M4 = 1.95. We are inter-
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ested in estimating a subset of the contrasts between the treatments, specifically
marginal mean differences M2−M1 = −0.60, M3−M1 = 0.20, and M4−M1 =
−0.85. Note that random effects were not generated in this simple simulation
study.
We tested the three methods described in the text (G-Computation, IPTW and
TMLE) for N = 15 and 50 simulated studies. We used logistic regression mod-
els conditional on the covariate for the generalized propensity score for IPTW
and TMLE. We ran two scenarios: incorrect and correct outcome model speci-
fication. For the correct scenario, linear regression models for the outcome ad-
justing for treatment type and covariate were used in G-Computation and TMLE.
For the incorrect scenario, the outcome was scaled to (0,1) and logistic regres-
sion models were used. We also display results for an unadjusted estimator that
merely takes the mean difference in treatment-specific outcomes when available.
Variance and confidence intervals were estimated using the nonparametric cluster
bootstrap (Efron and Tibshirani, 1994) where study is considered the cluster (and
arms are the individual observations). In Table 2, we present statistics describing
the quality of the estimation of all contrasts with treatment 1. These statistics are
the percent finite sample bias (“% Bias”), the standard deviation of the estimates
over the simulated data (“SE-MC”), the bootstrap-estimated standard error (“SE-
BS”), and the percentage of the 95% confidence intervals that capture the true
effect size (“% Cov”). Bootstrap resamples that did not allow for an estimate of
the contrast (i.e. if either of the treatments did not appear in the resampled data
set) were discarded, potentially biasing this standard error estimate.
The unadjusted estimator was greatly biased for the first and third contrasts, in-
dicating that those two contrasts were highly confounded by the simulated study-
level covariate. The correctly specified G-Computation estimator had the lowest
bias throughout, the smallest standard errors, and near optimal confidence inter-
val coverage. This is to be expected as G-Computation is a function of maximum
likelihood parameter estimates with correct parametric specification of the neces-
sary component of the likelihood (namely, the conditional mean of the outcome).
However, with an incorrectly specified outcome model, the estimator was biased
which caused the coverage to suffer for the third contrast.
IPTW was the most biased estimator and also had the largest variance. The
bias largely dissipated when the sample size was increased to N = 50 studies.
IPTW had good coverage except for the third treatment contrast where treatment
4 was rare. The slower convergence of IPTW in the contrast involving treatment 4
can be explained by a higher variance of the estimated weights for that treatment
compared to the others. The performance of IPTW has previously been seen to
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suffer when data support for certain exposure levels is sparse (i.e. under near
practical positivity violations) (Gruber and van der Laan, 2010). Truncation of
the propensity score at 5% and 10% respectively (that is, replacing the bottom p%
of the propensity score with the pth percentile) (Cole and Herna´n, 2008) increases
the bias for the first and third contrasts while reducing the variance, with no effect
on the coverage (results not shown).
TMLE with correct outcome model specification had bias comparable to G-
Computation but slightly higher for N = 15. For N = 50, the standard error
of TMLE was comparable to that of G-Computation but for N = 15 it was up
to 80 times larger. Regardless, correctly specified TMLE had good coverage
throughout. Notably, the bootstrap standard error estimates were comparable to
the Monte-Carlo standard error for N = 50 but diverged for IPTW and TMLE
when N = 15. Certain implementations of TMLE are more sensitive to near prac-
tical positivity violations (Gruber and van der Laan, 2010, Porter et al., 2011,
Schnitzer et al., 2013), hence the need for the robust version that involves the
logistic regression for the update of the predictions (as described in Gruber and
van der Laan 2010 and for our specific setting in Section 5.3). When the outcome
model was misspecified, TMLE also accrued bias for the first and third contrasts,
with magnitude comparable to the misspecified G-Computation. This bias de-
creased with more studies due to the double robustness of TMLE (making this
estimator consistent even when the outcome model is misspecified). Coverage
only suffered for the third contrast which was the most biased.
7 Application: Antibiotic use on methicillin-resistant
Staphylococcus aureus infection
We illustrate this causal inference approach and the adapted estimation methods
in network meta-analysis with an example from infectious disease research. An
increase in MRSA has spurred investigation of comparative efficacy of different
antibiotic treatment options. While the antibiotic vancomycin has been the stan-
dard treatment for decades, treatment failures have been noted in patients with
serious infections (Liu et al., 2011). Interest therefore lies in whether alternative
antibiotics are as effective as the standard. Bally et al. (2012) performed a system-
atic review and Bayesian network meta-analyses of RCTs of parenteral antibiotics
used for treating hospitalized adults with complicated skin and soft-tissue infec-
tions (cSSTIs) and hospital-acquired or ventilator-associated pneumonia.
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Table 2: Simulation: Quality of treatment contrast estimation with a Gaussian
outcome (two-arm studies, 1000 simulated datasets).
% Bias SE-MC SE-BS(% Cov)
N 15 50 15 50 15 50
Correctly specified models
M2−M1 =−0.6
G-Comp 0 0 0.04 0.02 0.04(91) 0.02(94)
IPTW 40 9 0.57 0.46 0.61(89) 0.41(92)
TMLE 4 0 0.27 0.03 0.44(96) 0.05(92)
M3−M1 = 0.20
G-Comp 1 0 0.04 0.02 0.04(91) 0.02(95)
IPTW -2 0 0.10 0.04 0.25(99) 0.05(97)
TMLE -1 -1 0.17 0.04 0.29(96) 0.04(93)
M4−M1 =−0.85
G-Comp 0 0 0.04 0.02 0.04(89) 0.02(93)
IPTW 81 3 0.76 0.74 0.62(63) 0.80(68)
TMLE -9 0 0.81 0.11 0.74(94) 0.21(95)
Misspecified outcome model
M2−M1 =−0.6
No adjustment 101 103 0.65 0.35 0.61(75) 0.34(52)
G-Comp 2 12 0.20 0.13 0.24(98) 0.11(94)
TMLE -8 -2 0.33 0.09 0.46(97) 0.11(96)
M3−M1 = 0.20
No adjustment 5 -7 0.37 0.20 0.38(92) 0.20(93)
G-Comp -1 7 0.20 0.12 0.18(99) 0.11(95)
TMLE 0 0 0.15 0.05 0.28(99) 0.05(96)
M4−M1 =−0.85
No adjustment 126 125 0.69 0.38 0.61(51) 0.36(18)
G-Comp 36 33 0.53 0.29 0.48(88) 0.24(80)
TMLE 44 -24 0.86 0.38 0.75(87) 0.36(75)
We consider the target population of interest to be the population of clini-
cal trial participants with suspected or confirmed MRSA cSSTIs or pneumonia,
with corresponding studies published until May 2012. The site of infection and
confirmation of MRSA represent important differences in the entrance criteria of
the various studies. 24 studies were found. Patients were randomized based on
suspicion of MRSA in all but three studies for which the protocol specified con-
firmation of presence of MRSA at baseline. 14 studies enrolled subjects with
cSSTIs, 7 studies enrolled subjects with hospital-acquired or ventilator-associated
pneumonia, and 3 studies allowed for either indication. The original network
meta-analysis of Bally et al. (2012) analyzed each infection site in separate analy-
ses and therefore obtained stratified estimates. Based on the theory we developed,
we can account for the potentially different treatment effects in each subpopula-
tion by controlling for subpopulation type as a covariate in the analysis. By doing
so, we ask a higher-level yet still clinically interesting question: “Are the alterna-
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tive therapies as effective as the standard antibiotic for the treatment of suspected
or confirmed MRSA?” Because infection site, MRSA confirmation, and study
year can potentially affect the choice of investigated therapies and the outcomes,
these three covariates (labeled Wi) should be adjusted for in order to minimize
confounding bias.
The outcome of interest is clinical test of cure for all subjects who received
at least one dose of treatment (a standard measure in infectious disease research).
Four papers evaluated the outcome only on a subset of patients selected post-
randomization; as this does not conform to our definition of the RCT-specific pa-
rameter of interest, we considered these outcomes missing. For our analysis, we
chose to compare vancomycin with the two most prevalent alternatives: telavancin
and linezolid. In total, 47 study arms evaluated one of these three treatments and
36 had an observed outcome. Of the remaining treatments, tigecycline, dapto-
mycin, and ceftaroline were each evaluated in three study arms, and a regime
of quinupristin/dalfopristin was evaluated in one arm. All of this information is
available in the data extraction Table 3.
We ran four methods to obtain estimates of the counterfactual relative risk of
both contrasts with the comparator vancomycin. The methods are 1) a ratio of
the unadjusted mean outcomes using all available arms (called “No Adjust”), 2) a
random effects regression for the arm-specific study outcomes using a log-link and
a study-specific intercept (“RE Arm”), 3) G-Computation where a random effects
logistic regression weighted by the inverse standard errors is used to predict the
conditional mean outcomes, and 4) TMLE with a weighted logistic random effects
model for the outcome and LASSO-penalized logistic regressions (to handle the
sparse data) for the propensity score and a missing data model using the R library
glmnet (Friedman et al., 2010). IPTW behaved erratically and was not included
in this example. The missing outcomes required that the TMLE algorithm include
fitting a model to estimate the probability of a missing outcome in each study;
the TMLE update step was therefore modified to use a product of the propensity
score and the probability of observing the outcome in place of ga(Wi). To estimate
the standard errors and confidence intervals, the built-in functions in the library
lme4 were used for the random effects model, and the clustered nonparametric
bootstrap (1000 times 54 resamples of 27 studies with replacement) was used for
the other methods.
The results of the network meta-analysis are presented graphically in Figure 2
(and numerically in the Appendix Figure 4). We also included the results of the
studies that contrasted the two treatments directly. For the comparison of tela-
vancin versus vancomycin, all estimators include the null in the confidence in-
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terval. The random effect regression and G-Computation produce estimates of
the relative risk close to one, indicating near equivalence of treatments while the
point estimate of TMLE was further from the null (in the direction of the superi-
ority of vancomycin). Notably, the confidence interval for the TMLE in the first
contrast is much wider than the others. The unadjusted method produced a point
estimate in the direction of the superiority of telavancin, demonstrating that the
correction for study-level confounding impacted the analysis. For the comparison
of linezolid versus vancomycin, the random effects regression, G-Computation
and TMLE agree on the superiority of linezolid. The original study by Bally et al.
(2012) also found some suggestion of a superior effect of linezolid compared to
vancomycin but for both subpopulations the confidence intervals were large and
spanned the null.
0.8 0.9 1.0 1.1 1.2
TMLE
G−Comp
RE Arm
No Adjust
Rubenstein 2011
Rubenstein 2011
Stryjewski 2006
Stryjewski et al, 2008
Stryjewski et al, 2008
Direct and NMA contrasts between telavancin and vancomycin
(a)
0.6 0.8 1.0 1.2 1.4
TMLE
G−Comp
RE Arm
No adjust
Wunderink et al, 2012
Itani et al, 2010
Rubenstein et al, 2001
Wunderink et al, 2003
Stevens et al, 2002
Stevens et al, 2002
Weigelt et al, 2005
Direct and NMA contrasts between linezolid and vancomycin
(b)
Figure 2: Risk ratio estimates and confidence intervals for clinical success at test
of cure for all studies with direct comparisons and all network meta-analysis meth-
ods for the contrasts between a) telavancin and vancomycin and b) linezolid and
vancomycin. Risk ratio values below one indicate superiority of vancomycin.
We can also easily obtain estimates of the contrast between telavancin and
linezolid. The G-Computation and TMLE produce risk ratios for clinical success
of 0.94 (95% confidence interval = 0.92,0.94) and 0.85 (0.71,1.12) respectively,
with G-Computation concluding the superiority of linezolid. As no RCT directly
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contrasted these two antibiotics, this demonstrates another general advantage of
network meta-analysis, which is the ability to formally compare treatments using
only indirect evidence of their relative performance.
If we are to interpret the summary statistics as estimates of the relative causal
effects of antibiotic choice on successful treatment, the causal assumptions in Sec-
tion 4.3 need to be satisfied. Each of the studies evaluated the clinical efficacy of
the treatments, which is defined on patients who had received at least one dose
of the study drug. Because randomized treatment was first-line therapy (admin-
istered intravenously in-hospital) and the success of treatment was determined
clinically, each trial estimated the relative effect under full adherence. No inter-
ference: No interference is credible in this case because all subjects were already
suspected or confirmed to have MRSA upon entry to the study. Therefore, the
choice of treatment in the other arm wouldn’t have an effect on existing infec-
tions nor the success of treatment. Unconfoundedness: The unconfoundedness
assumption relies on whether year, infection type, and whether MRSA was con-
firmed were sufficient to control for confounding at the study-level. This assump-
tion could be violated if prognostic demographic variables were involved in the
study design stage. However, prognostic markers such as diabetes and peripheral
vascular disease (for cSSTI) and mechanical ventilation, APACHE II score, clin-
ical markers of severity, and presence of organ dysfunction (for pneumonia) are
unlikely to determine the choice of initial therapy (Lipsky et al., 2011, Nieder-
man, 2010). Consistency: The dosage regimens varied somewhat across studies
but were all considered to be at therapeutic levels. However, the length of time
to the evaluation time point for each treatment type varied within and between
studies (e.g. 7-14 days for telavancin versus 12-28 days for linezolid). If this
corresponds to meaningfully different treatment durations (and/or periods of time
lapsed before evaluation), this would indicate different definitions of interventions
across studies, and thus a violation of the consistency assumption. Positivity: All
subjects in the study were indicated to receive any of the treatments evaluated.
8 Summary
In this paper, we nonparametrically define the parameter of interest in a net-
work meta-analysis with direct and indirect comparisons using the counterfactual
framework often employed in causal inference. This definition of the parame-
ter of interest is model-independent and is interpretable on what we define as a
metapopulation, the union of all superpopulations. Such an approach allows for a
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straight-forward description of what is being estimated, which is accessible even
without an understanding of the estimation methods being used. In particular,
we can interpret the marginal effects defined in this paper as the relative mean
outcome had all subjects in the metapopulation been assigned to each treatment
versus another. If a specific population is of interest and not represented by the
metapopulation, with some conditions it may also be possible to more generally
transport effect estimation, as described by Bareinboim and Pearl (2013).
We have presented a set of conditions under which identifiability of the pa-
rameter of interest is possible. Identifiability allows for a clear description of
when the parameter of interest can and cannot be estimated. For instance, the
non-interference requirement casts doubt on the synthesis of studies that allow for
treatment switching, crossover, or group contamination. The assumptions that we
made allowed for the simplification of the relevant components of the observed
data likelihood so that arm-based inference is possible.
One might alternatively specify the RCT-estimated contrast as the “outcome
of interest” (rather than use the arm-specific outcome as we did). However, un-
der this alternative, the propensity score would then be defined as the probability
of a trial directly contrasting a given treatment pair. For standard network meta-
analysis sample sizes, this would most often produce practical positivity problems,
indicating the need for extrapolation using the outcome model (and thereby cre-
ating estimators that are very sensitive to model misspecification). In particular,
two treatments that had never been directly compared would have no data support
in this model.
If all treatments are selected completely at random into studies (or if only
two treatments have ever been available to compare) then a standard unadjusted
analysis using those arms assigned the desired treatments would be consistent. If
we weaken this assumption and replace it with conditional exchangeability, then
the estimators introduced in this paper are appropriate in that they allow for the
adjustment of study-level covariates.
Our methods also allow for a wider inclusion criteria of studies in a systematic
review. It is often the case that systematic reviews will exclude studies because
they do not evaluate the exact desired clinical endpoint. Using our proposed meth-
ods, we can avoid selection bias due to studies excluded only for this reason. To
do so, we would artificially censor the outcomes of studies that do not estimate the
desired outcome-type of interest. The censored outcomes of these studies might
then be considered “missing at random” conditional on the study baseline infor-
mation which should still be included in the analysis (both in the propensity score
model and the missing data model).
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For the analysis of continuous individual-level outcomes, we assumed inde-
pendence between the sample mean and standard deviation within each study
arm. While we chose to present our identifiability argument under this assump-
tion, it is not ultimately necessary. However, it is not straight-forward to propose
a valid Monte Carlo or Bayesian estimation approach to the setting with depen-
dent sample means and standard deviations. In some cases, it may be possible to
transform the individual-level data to remove the skew, but this relies on access to
each study’s raw data, in which case an individual patient data analysis would be
preferable.
In the simulation study, we show that certain estimators adopted from the
causal inference literature can produce valid estimates of effect contrasts under
the identifiability conditions described. In particular, G-Computation and TMLE
might lend themselves well to network meta-analysis, which is characterized by
small sample sizes and low prevalence for certain treatments. IPTW was seen
to be sensitive to rare treatment assignment and G-Computation and TMLE were
seen to be somewhat sensitive to model misspecification. Some general benefits
of using TMLE are that it is double robust and can incorporate nonparametric (or
machine learning) estimation of the propensity score and outcome model which
can help avoid bias from model misspecification (van der Laan and Rose, 2011).
More methods development and investigations are needed to address extremely
rare treatments and how (or whether) TMLE can be adapted to be robust in this
setting.
The application we presented compared the results of random effects regres-
sion, G-Computation, and TMLE in a network meta-analysis of the relative effi-
cacy of treatment options for MRSA infection. The random effects regression and
G-Computation produced small confidence intervals relative to the direct contrasts
of the individual RCTs though TMLE only did for one comparison investigated. In
contrast to the analysis in the original article that used unadjusted contrast-based
hierarchical Bayesian modeling on the separate subpopulations of infection types,
our analyses concluded that there is evidence to support the superiority of line-
zolid over vancomycin. We also noted the poor stability of IPTW in this example
and generally do not recommend this estimator when the data support for cer-
tain treatment levels is sparse. Finally, using this data example, we demonstrated
how the causal assumptions should be listed and critiqued in order to stimulate
discussion about the appropriateness of causal interpretations in specific contexts.
The framework we present formally assumes that we are restricting our anal-
yses to studies evaluating a common parameter-type. If there was only partial-
adherence in the RCTs, our framework does not allow for the mixing of intent-
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to-treat parameter estimates with adherence-adjusted parameter estimates. (Esti-
mation of the adherence-adjusted parameters in RCTs is described in Herna´n and
Herna´ndez-Dı´az 2012.) The same restriction applies to the results of observational
studies if the parameter type estimated in the observational study is not the same as
in the clinical trials. Specifically, treatment adherence and outcome need to be de-
fined identically across studies, and all studies whose endpoints are included must
estimate the same mean treatment-specific counterfactual outcome. Although it
is common practice to include different parameter types in a meta-analysis, our
formalization of the target parameter reveals that a causal interpretation of the
resulting effect estimate may be quite challenging.
In addition to the issues we describe, there are many other concerns about
aggregating study results in various settings. For instance, one might question
the independence between RCTs happening close in time, or the systematic re-
view inclusion criteria. We believe our framework provides additional structure to
the ongoing discussion about the validity of network meta-analysis and will help
stimulate solutions to the remaining challenges.
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A Appendix
A.1 Proof of identifiability under structural independence
The joint counterfactual distribution can be decomposed as f (Oai )= f1(O
a
i ) f2(O
a
i )
where f1(Oai ) = QW (Wi)QY¯ (Y¯
a
i j | Nai j,Wi) and
f2(Oai ) =Qn(ni |Wi)gA\ j(Aai\ j | ni,Wi)QN(Nai j | Aai\ j,ni,Wi)QS(Sai j | Nai j,Wi)×
∏
j∗ 6= j
QY¯ ,S(Y¯
a
i j∗,S
a
i j∗ | Nai j∗,Aai j∗,Wi)QN(Nai j∗ | Aai\ j,ni,Wi).
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LetA be the set of possible treatments. The target of our analysis is the study
arm counterfactual outcome under treatment a, or E(Y¯ ai j) =M
a. This mean can be
written as∫
Wi
∞
∑
ni=1
∑
Ai\ j∈{A \a}
∞
∑
Ni\ j=1
∞
∑
Ni j=1
∫ ∞
0
∫ ∞
−∞
∫ ∞
0
∫ ∞
−∞
Y¯ ai j f (O
a
i )dY¯
a
i jdS
a
i jdY¯
a
i j∗dS
a
i j∗dWi
=
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∑
ni=1
∑
Ai\ j∈{A \a}
∞
∑
Ni\ j=1
∞
∑
Ni j=1
∫ ∞
0
∫ ∞
−∞
∫ ∞
0
∫ ∞
−∞
Y¯ ai jQY¯ (Y¯
a
i j | Nai j,Wi)dY¯ ai j×
f2(Oai )QW (Wi)dS
a
i jdY¯
a
i j∗dS
a
i j∗dWi
=
∫
Wi
∞
∑
ni=1
∑
Ai\ j∈{A \a}
∞
∑
Ni\ j=1
∞
∑
Ni j=1
∫ ∞
0
∫ ∞
−∞
∫ ∞
0
E(Y¯ ai j | Nai j,Wi) f2(Oai )QW (Wi)dSai jdY¯ ai j∗dSai j∗dWi
where the integral for Wi can be a multiple integral, taken over the domain of
potentially multivariate Wi. Now we note that for identically distributed and con-
ditionally independent draws Yi jk
E(Y¯ ai j | Nai j,Wi) = E(
1
Nai j
Nai j
∑
k=1
Y ai jk | Nai j,Wi) = E(Y ai jk |Wi)
because we assume that the study size has no effect on the individual-level out-
come. It follows that E(Y¯ ai j | Nai j,Wi) is conditionally independent of Nai j. The
expression for Ma then simplifies to
∫
Wi E(Y¯
a
i j | Nai j,Wi)QW (Wi)dWi. In order for
the conditional expectation to be estimable from the observed data, we require the
unconfoundedness assumption Y¯ ai j⊥⊥Ai j = a |Nai j,Wi. With respect to the example
DAG in Figure 1(a), this corresponds to having measured all components of W2i.
If this assumption holds in addition to the consistency of treatment for Y¯i j, we may
write Ma =
∫
W E(Y¯i j |Wi,Ai j = a)QW (Wi)dW to establish identifiability.
A.2 Identifiability without assuming structural independence
It may not be plausible to assume conditional independence between Y¯ ai j and S
a
i j. In
this case, the relevant part of the distribution of the observed data counterfactuals
is
f3(Oai ) = QW (Wi)Qn(ni |Wi)gA\ j(Aai\ j | ni,Wi)QN(Nai j | Aai\ j,ni,Wi)QY¯ ,S(Y¯ ai j,Sai j | Nai j,Wi).
The target parameter can be estimated as a multiple integral over each Y¯ ai j and
each density component in f3(Oai ). Identifiability in this case requires a list of
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unconfoundedness assumptions: Aai\ j⊥⊥Ai j = a | ni,Wi, Nai j | Ai j = a | Aai\ j,ni,Wi,
and Y¯ ai j,S
a
i j⊥⊥Ai j = a | Nai j,Wi. Assuming the DAG in Figure 1(a) in the main
manuscript, this requires having measured all components of W1i, W2i, and W3i.
It also requires the consistency assumption for Ai\ j, Ni j, Y¯i j and Si j. Under these
assumptions, we can rewrite the relevant density component as
f3(Oai ) =QW (Wi)Qn(ni |Wi)gA\ j(Ai\ j | Ai j = a,ni,Wi)QN(Ni j | Ai j = a,Ai\ j,ni,Wi)×
QY¯ ,S(Y¯i j,Si j | Ai j = a,Ni j,Wi).
Since each component of this density is estimable from the data, we have identifi-
ability of the target parameter in this case as well.
A.3 Efficiency and Consistency of TMLE
The local semiparametric efficiency and estimation consistency of the TMLE we
describe can be derived very similarly to the standard observational data setting
(with a single categorical exposure variable) for the estimation of the average
treatment effect (van der Laan and Rose, 2011). To give more insight into how
this extends to the network meta-analysis case, we present some additional details
and a proof of double robustness.
The efficient influence function for parameter of interest Ma with only aggre-
gate observed data is
D∗i j(O) =
{
Y¯i j−E(Y¯ ai |Wi,a ∈ Ai)
} I(a ∈ Ai)
ga(Wi)
+E(Y¯ ai |Wi,a ∈ Ai)−Ma.
Note that the TMLE update step produces values of ˆ¯Y a,∗i j that solve the empirical
efficient influence function equation:
N
∑
i=1
ni
∑
j=1
(Y¯i j− ˆ¯Y a,∗i j )
I(a ∈ Ai)
ga(Wi)
+( ˆ¯Y a,∗i j − MˆaT MLE) = 0
so that it follows that the TMLE is a locally efficient estimator (van der Laan and
Robins, 2003, Tsiatis, 2006). Specifically, the logistic regression update step with
single covariate Xi = I(a∈Ai)/ga(Wi) solves the score equation∑Ni=1∑nij=1 Xi(Y¯i j−
ˆ¯Y a,∗i j ) = 0 and in the last TMLE step we set Mˆ
a
T MLE = ∑
N
i=1∑
ni
j=1
ˆ¯Y a,∗i j .
First suppose that for increasing values of ∑Ni=1 I(a ∈ Ai), the generalized
propensity score ga(Wi) converges to some g˜a(Wi) 6= P(a ∈ Ai |Wi) but that ˆ¯Y a,∗i j
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converges to the true values E(Y¯i j |Wi,a ∈ Ai). We then have that
E
[{
Y¯i j−E(Y¯ ai |Wi,a ∈ Ai)
}× I(a ∈ Ai)
g˜a(Wi)
+E(Y¯ ai |Wi,a ∈ Ai)−Ma
]
= E
[
E
{
Y¯i j−E(Y¯ ai |Wi,a ∈ Ai) |Wi,a ∈ Ai
}× I(a ∈ Ai)
g˜a(Wi)
+E(Y¯ ai |Wi,a ∈ Ai)−Ma
]
= E
[
0× I(a ∈ Ai)
g˜a(Wi)
]
+0 = 0
Now suppose that ga(Wi) converges to the true values P(a ∈ Ai |Wi) but that
ˆ¯Y a,∗i j converges to some function Q˜a(Wi) 6= E(| Yi j |Wi,a ∈ Ai). We then have that
E
[{
Y¯i j− Q˜a(Wi)
}× I(a ∈ Ai)
P(a ∈ Ai |Wi) + Q˜a(Wi)−M
a
]
= E
[{
Y¯i j− Q˜a(Wi)
}×E{ I(a ∈ Ai)
P(a ∈ Ai |Wi)
}
+ Q˜a(Wi)−Ma
]
= E
[{
Y¯i j− Q˜a(Wi)
}×1+ Q˜a(Wi)−Ma]
= E
[
Y¯i j−Ma
]
= 0
Therefore, if either of the models for E(Y¯ ai |Wi,a ∈ Ai) or P(a ∈ Ai |Wi) are con-
sistent, then the TMLE for Ma is also consistent as the efficient influence function
equation is consistent for Ma.
A.4 Data extraction information and numerical results for the
example of antibiotic use on methicillin-resistant Staphy-
lococcus aureus infection
Table 3 presents the full study list from the systematic review of Bally et al. (2012)
and the data that we used in the analysis in Section 7. Table 4 presents the numer-
ical results that we obtained from our analyses, corresponding with Figure 2. The
full reference list is below.
References for the MRSA application
Arbeit, R. D., D. Maki, F. P. Tally, E. Campanaro, B. I. Eisenstein, and Dapto-
mycin 98-01 and 99-01 Investigators (2004): “The safety and efficacy of dap-
tomycin for the treatment of complicated skin and skin-structure infections,”
Clinical Infectious Diseases, 38, 1673–1681.
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Table 3: Data extraction table for the network meta-analysis of antibiotic use on
methicillin-resistant Staphylococcus aureus infection
Publication Events Ni Ai StudyID Year Infection Confirmed MRSA
at baseline
Katz et al., 2008 42 48 vancomycin 1 2007 cSSTI 0
36 48 daptomycin 1 2007 cSSTI 0
Arbeit et al., 2004 162 266 vancomycin 2 2001 cSSTI 0
165 264 daptomycin 2 2001 cSSTI 0
235 292 vancomycin 3 2000 cSSTI 0
217 270 daptomycin 3 2000 cSSTI 0
Breedtet al.,2005 216 250 vancomycin 4 2003 cSSTI 0
212 253 tigecycline 4 2003 cSSTI 0
Sacchidanand et al., 2005 196 255 vancomycin 5 2003 cSSTI 0
203 268 tigecycline 5 2003 cSSTI 0
Stryjewski et al., 2008 307 429 vancomycin 6 2006 cSSTI 0
309 426 telavancin 6 2006 cSSTI 0
360 489 vancomycin 7 2006 cSSTI 0
348 472 telavancin 7 2006 cSSTI 0
Stryjewski et al., 2006 81 95 vancomycin 8 2004 cSSTI 0
82 100 telavancin 8 2004 cSSTI 0
Corey et al., 2010 297 347 vancomycin 9 2007 cSSTI 0
304 351 ceftaroline 9 2007 cSSTI 0
Wilcox et al., 2010 289 338 vancomycin 10 2007 cSSTI 0
291 342 ceftaroline 10 2007 cSSTI 0
Talbot et al., 2007 26 32 vancomycin 11 2005 cSSTI 0
59 67 ceftaroline 11 2005 cSSTI 0
Weigelt et al., 2005 402 573 vancomycin 12 2003 cSSTI 0
439 583 linezolid 12 2003 cSSTI 0
Stevens et al., 2002 54 87 vancomycin 13 1999 cSSTI 0
64 99 linezolid 13 1999 cSSTI 0
16 32 vancomycin 14 1999 pneumonia 0
20 39 linezolid 14 1999 pneumonia 0
Wunderink et al., 2003 128 302 vancomycin 15 2000 pneumonia 0
135 321 linezolid 15 2000 pneumonia 0
Rubenstein et al., 2001 73 192 vancomycin 16 1999 pneumonia 0
85 203 linezolid 16 1999 pneumonia 0
Rubenstein et al., 2011 221 374 vancomycin 17 2007 pneumonia 0
214 372 telavancin 17 2007 pneumonia 0
228 380 vancomycin 18 2007 pneumonia 0
227 377 telavancin 18 2007 pneumonia 0
Fagon et al., 2000 67 148 vancomycin 19 1996 pneumonia 0
65 150 quinupristin/
dalfopristin
19 1996 pneumonia 0
Lin et al., 2008 NA 33 linezolid 20 2005 cSSTI 0
NA 29 vancomycin 20 2005 cSSTI 0
NA 38 linezolid 21 2005 pneumonia 0
NA 40 vancomycin 21 2005 pneumonia 0
Kohno et al., 2007 NA 51 linezolid 22 2004 cSSTI 0
NA 26 vancomycin 22 2004 cSSTI 0
NA 31 linezolid 23 2004 pneumonia 0
NA 17 vancomycin 23 2004 pneumonia 0
Florescu et al., 2008 NA 70 tigecycline 24 2005 cSSTI 0
NA 23 vancomycin 24 2005 cSSTI 0
Itani et al., 2010 223 276 linezolid 25 2007 cSSTI 1
196 266 vancomycin 25 2007 cSSTI 1
Wunderink et al., 2008 NA 30 linezolid 26 2005 pneumonia 1
NA 20 vancomycin 26 2005 pneumonia 1
Wunderink et al., 2012 102 186 linezolid 27 2010 pneumonia 1
92 205 vancomycin 27 2010 pneumonia 132
Table 4: Risk ratio estimates, standard errors and 95% confidence intervals for rel-
ative effects of antibiotics telavancin (TEL), linezolid (LIN), and mainstay therapy
vancomycin (VAN)
TEL vs VAN LIN vs VAN TEL vs LIN
Method Est SE 95% CI EST SE 95% CI
No Adjust 1.04 0.028 (0.99,1.10) 0.92 0.027 (0.87,0.97) 1.13 0.045 (1.05,1.22)
RE Arm 1.00 0.010 (0.98,1.02) 1.08 0.012 (1.05,1.10) 0.92 0.014 (0.89,0.95)
G-Comp (RE) 1.00 0.003 (1.00,1.00) 1.06 0.006 (1.06,1.09) 0.94 0.005 (0.92,0.94)
TMLE (RE) 0.89 0.106 (0.75,1.19) 1.05 0.012 (1.03,1.07) 0.85 0.102 (0.71,1.12)
Breedt, J., J. Teras, J. Gardovskis, F. J. Maritz, T. Vaasna, D. P. Ross, M. Gioud-
Paquet, N. Dartois, E. J. Ellis-Grosse, E. Loh, and Tigecycline 305 cSSSI Study
Group (2005): “Safety and efficacy of tigecycline in treatment of skin and skin
structure infections: results of a double-blind phase 3 comparison study with
vancomycin-aztreonam,” Antimicrobial Agents and Chemotherapy, 49, 4658–
4666.
Corey, G. R., M. H. Wilcox, G. H. Talbot, D. Thye, D. Friedland, T. Baculik, and
CANVAS 1 investigators (2010): “Canvas 1: the first phase iii, randomized,
double-blind study evaluating ceftaroline fosamil for the treatment of patients
with complicated skin and skin structure infections,” Journal of Antimicrobial
Chemotherapy, 65 Suppl 4, iv41–51.
Fagon, J., H. Patrick, D. W. Haas, A. Torres, C. Gibert, W. G. Cheadle, R. E.
Falcone, J. D. Anholm, F. Paganin, T. C. Fabian, and F. Lilienthal (2000):
“Treatment of gram-positive nosocomial pneumonia. prospective randomized
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monia group,” American Journal of Respiratory and Critical Care Medicine,
161, 753–762.
Florescu, I., M. Beuran, R. Dimov, A. Razbadauskas, M. Bochan, G. Fichev,
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